Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  CEL-SCI Corporation       US1508374097

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine, is being developed as a potential therapeutic agent... 
Sector
Biotechnology & Medical Research
Calendar
02/09 | 04:00pmPresentation
More about the company
Financials ($)
Sales 2015 0,26 M
EBIT 2015 -27,2 M
Net income 2015 -
Debt 2015 -
Yield 2015 -
Sales 2016 0,30 M
EBIT 2016 -28,4 M
Net income 2016 -
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 253x
Capi. / Sales 2016 219x
Capitalization 65,8 M
More Financials
Latest news on CEL-SCI CORPORATION
01/29 CEL SCI : Gets Regulatory OK to Expand Its Phase III Head and Neck Cancer Trial ..
01/26 CEL SCI : Receives Regulatory Clearance to Expand Its Phase III Head and Neck Ca..
01/14 CEL SCI : 2014 Patient Enrollment Increases Eight-Fold over 2013 in its Phase II..
01/12 CEL SCI : Updated Coverage Report Focuses on CEL-SCI Corporation
01/09 CEL SCI : to Present at Biotech Showcase 2015
01/06 CEL SCI : NEW STORY Date Set For Arbitration Trial between CEL-SCI And Clinical ..
01/06 CEL SCI : Date Set for Arbitration Trial Between CEL-SCI and Clinical Research O..
01/05 CEL SCI : NEW STORY CEL-SCI's 2014 Patient Enrollment Increases Eight-Fold Over ..
More news
Sector news Bio Therapeutic Drugs
06:14a PHARMACYCLICS : Johnson & Johnson: U.S. FDA Approves IMBRUVICA (ibrutinib) for t..
01/29DJValeant to Buy Prostate-Cancer Drug From Dendreon
01/29DJValeant in Deal to Buy Prostate-Cancer Drug Provenge From Dendreon
Plus d'actualités du secteur Bio Therapeutic Drugs
Comments 
Advertisement
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF